Crinetics Pharmaceuticals (CRNX) Retained Earnings (2017 - 2026)

Crinetics Pharmaceuticals' Retained Earnings history runs 10 years deep, the most recent figure standing at -$1.5 billion for Q1 2026.

• In Q1 2026, Retained Earnings fell 47.33% year-over-year to -$1.5 billion; the TTM figure through Mar 2026 stood at -$1.5 billion (down 47.33% YoY), while the FY2025 annual figure was -$1.4 billion, down 147288.68% from the prior year.
• Retained Earnings was -$1.5 billion for Q1 2026 at Crinetics Pharmaceuticals, down from -$1.4 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $2.0 million in Q3 2024 to a low of -$1.5 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$602.6 million across 5 years, with a median of -$485.2 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings surged 100.34% in 2024, then plunged 147288.68% in 2025.
• A 5-year view of Retained Earnings shows it stood at -$439.2 million in 2022, then surged by 100.22% to $977000.0 in 2023, then retreated by 1.43% to $963000.0 in 2024, then slumped by 147288.68% to -$1.4 billion in 2025, then declined by 9.02% to -$1.5 billion in 2026.
• The last three Retained Earnings figures came in at -$1.5 billion (Q1 2026), -$1.4 billion (Q4 2025), and -$1.3 billion (Q3 2025), per Business Quant data.